<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 07 Jun 2021 07:30:29 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>首个国产重组凝血因子VIII临床研究正式刊登于国际权威杂志《Haemophilia》</title><link>https://mp.weixin.qq.com/s/vV4BN8cYHEOUcvZnYPFXQw</link><description></description><content:encoded><![CDATA[首个国产重组凝血因子VIII临床研究正式刊登于国际权威杂志《Haemophilia》]]></content:encoded><pubDate>Sun, 06 Jun 2021 23:50:02 +0800</pubDate></item><item><title>ASCO 2021：新机会TOP10</title><link>https://mp.weixin.qq.com/s/ne1G1Ciw7pXljgO8hKJRuQ</link><description></description><content:encoded><![CDATA[ASCO 2021：新机会TOP10]]></content:encoded><pubDate>Sun, 06 Jun 2021 23:50:02 +0800</pubDate></item><item><title>ORR高达81.3%！法米替尼+卡瑞利珠单抗+化疗一线治疗「免疫调节型」三阴乳腺癌2期数据出炉</title><link>https://mp.weixin.qq.com/s/v5yOYWStxjNd893rmftOsw</link><description></description><content:encoded><![CDATA[ORR高达81.3%！法米替尼+卡瑞利珠单抗+化疗一线治疗「免疫调节型」三阴乳腺癌2期数据出炉]]></content:encoded><pubDate>Sun, 06 Jun 2021 23:50:02 +0800</pubDate></item><item><title>聚焦ASCO：武田、迪哲、再鼎、杨森「同台竞技」，EGFR exon20抑制剂哪家强？</title><link>https://mp.weixin.qq.com/s/MBTqrDUz36MsUB2IYx6z0A</link><description></description><content:encoded><![CDATA[聚焦ASCO：武田、迪哲、再鼎、杨森「同台竞技」，EGFR exon20抑制剂哪家强？]]></content:encoded><pubDate>Sun, 06 Jun 2021 23:50:02 +0800</pubDate></item><item><title>聚焦ASCO 2021：肝癌研究摘要选读</title><link>https://mp.weixin.qq.com/s/R0mtkD_nkRU2gLyWQd189w</link><description></description><content:encoded><![CDATA[聚焦ASCO 2021：肝癌研究摘要选读]]></content:encoded><pubDate>Sun, 06 Jun 2021 23:50:02 +0800</pubDate></item><item><title>司美格鲁肽减肥适应症获FDA批准！每周皮下注射1次，68周减重18%</title><link>https://mp.weixin.qq.com/s/F7MJjUYPT4ZtjNuqrSbJOg</link><description></description><content:encoded><![CDATA[司美格鲁肽减肥适应症获FDA批准！每周皮下注射1次，68周减重18%]]></content:encoded><pubDate>Sat, 05 Jun 2021 08:52:43 +0800</pubDate></item><item><title>中国首个批准心衰药Entresto新适应症，治疗高血压</title><link>https://mp.weixin.qq.com/s/zNgszyHbMzTcydgi-Eg7pw</link><description></description><content:encoded><![CDATA[中国首个批准心衰药Entresto新适应症，治疗高血压]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:19:15 +0800</pubDate></item><item><title>罗氏新一代CD20单抗「奥妥珠单抗」 在华获批上市</title><link>https://mp.weixin.qq.com/s/9B9IBiNQEaK6gV228j7nkA</link><description></description><content:encoded><![CDATA[罗氏新一代CD20单抗「奥妥珠单抗」 在华获批上市]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:19:15 +0800</pubDate></item><item><title>8部委联合发文，进一步规范高值医用耗材国采</title><link>https://mp.weixin.qq.com/s/V8wC2XAhRzfmayd_9D1ofg</link><description></description><content:encoded><![CDATA[8部委联合发文，进一步规范高值医用耗材国采]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:19:15 +0800</pubDate></item><item><title>直播预告 | ASCO 2021最值得关注Top10新机会深度解析</title><link>https://mp.weixin.qq.com/s/wwewGDV_zMLDYm7_S-ql1A</link><description></description><content:encoded><![CDATA[直播预告 | ASCO 2021最值得关注Top10新机会深度解析]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:19:15 +0800</pubDate></item><item><title>诺诚健华首次公布泛FGFR抑制剂gunagratinib最新临床数据公布</title><link>https://mp.weixin.qq.com/s/lVhZ-3qO0juFkiCXl5B35Q</link><description></description><content:encoded><![CDATA[诺诚健华首次公布泛FGFR抑制剂gunagratinib最新临床数据公布]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:19:15 +0800</pubDate></item><item><title>康柏西普新适应症临床申请获批，用于早产儿视网膜病变</title><link>https://mp.weixin.qq.com/s/7ykx5GQ6KAPwAIN_yEDE7Q</link><description></description><content:encoded><![CDATA[康柏西普新适应症临床申请获批，用于早产儿视网膜病变]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:19:15 +0800</pubDate></item><item><title>和誉医药同日任命两名职能部门高管</title><link>https://mp.weixin.qq.com/s/v3_vN7cOKkeBaAxjvFqvbA</link><description></description><content:encoded><![CDATA[和誉医药同日任命两名职能部门高管]]></content:encoded><pubDate>Fri, 04 Jun 2021 17:19:15 +0800</pubDate></item><item><title>信达PD-1第3项适应症获批，一线治疗鳞状NSCLC</title><link>https://mp.weixin.qq.com/s/uZLWH5LSQy0EcHC1QdAFrA</link><description></description><content:encoded><![CDATA[信达PD-1第3项适应症获批，一线治疗鳞状NSCLC]]></content:encoded><pubDate>Thu, 03 Jun 2021 16:40:00 +0800</pubDate></item><item><title>ORR达60% ! 强生BCMA/CD3双抗获FDA突破性疗法认定</title><link>https://mp.weixin.qq.com/s/_inO2z4jB5QphzjewD91Ng</link><description></description><content:encoded><![CDATA[ORR达60% ! 强生BCMA/CD3双抗获FDA突破性疗法认定]]></content:encoded><pubDate>Thu, 03 Jun 2021 16:40:00 +0800</pubDate></item><item><title>贝达药业「埃克替尼片」新适应症获批，NSCLC术后辅助治疗</title><link>https://mp.weixin.qq.com/s/2lqrSb6uJhUUBu2qDUmK8g</link><description></description><content:encoded><![CDATA[贝达药业「埃克替尼片」新适应症获批，NSCLC术后辅助治疗]]></content:encoded><pubDate>Thu, 03 Jun 2021 16:40:00 +0800</pubDate></item><item><title>多肽类药物开发企业圣诺生物今日科创板上市</title><link>https://mp.weixin.qq.com/s/qPn30TmD7ulTegAdpeKdGA</link><description></description><content:encoded><![CDATA[多肽类药物开发企业圣诺生物今日科创板上市]]></content:encoded><pubDate>Thu, 03 Jun 2021 16:40:00 +0800</pubDate></item><item><title>诺华Cosentyx 新适应症获FDA批准，首次获批用于儿科人群</title><link>https://mp.weixin.qq.com/s/Ytalre2A_aUNUEk9JVawlQ</link><description></description><content:encoded><![CDATA[诺华Cosentyx 新适应症获FDA批准，首次获批用于儿科人群]]></content:encoded><pubDate>Thu, 03 Jun 2021 16:40:00 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 南京站</title><link>https://mp.weixin.qq.com/s/6Gk4X7kvELFtzkP3S1gjCA</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 南京站]]></content:encoded><pubDate>Thu, 03 Jun 2021 16:40:00 +0800</pubDate></item><item><title>Panacea Venture/戴尔家族办公室联手发起并筹集2亿美元的SPAC</title><link>https://mp.weixin.qq.com/s/TzlKKt4UbzP41JwCzkeRVw</link><description></description><content:encoded><![CDATA[Panacea Venture/戴尔家族办公室联手发起并筹集2亿美元的SPAC]]></content:encoded><pubDate>Thu, 03 Jun 2021 16:40:00 +0800</pubDate></item></channel></rss>